{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:57Z","timestamp":1786980537950,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s10072-009-0211-y","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T15:25:36Z","timestamp":1268925936000},"page":"299-306","source":"Crossref","is-referenced-by-count":33,"title":["Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Alessandro","family":"Salviati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro P.","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Borsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,19]]},"reference":[{"key":"211_CR1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensonn E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry\u2019s disease: ceramidetrihexosidase deficiency. New Engl J Med 276:1163\u20131167","journal-title":"New Engl J Med"},{"key":"211_CR2","first-page":"3733","volume-title":"The metabolic and molecular basis of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng ME (2001) \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, vol 3, 8th edn. McGraw-Hill, New York, pp 3733\u20133774","edition":"8"},{"key":"211_CR3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750\u2013760","journal-title":"J Med Genet"},{"key":"211_CR4","first-page":"183","volume-title":"Fabry disease: perspectives from 5\u00a0years of FOS","author":"A Mehta","year":"2006","unstructured":"Mehta A, Widmer U (2006) Natural history of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5\u00a0years of FOS. Oxford Pharmagenesis, Oxford, pp 183\u2013188"},{"key":"211_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 336 patients in the Fabry outcome survey. Eur J Clin Invest 34:236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"211_CR6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184\u2013192","journal-title":"J Inherit Metab Dis"},{"key":"211_CR7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","volume":"79","author":"S Buechner","year":"2008","unstructured":"Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, Mignani R, Parini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W (2008) Central nervous system involvement in Anderson\u2013Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249\u20131254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"211_CR8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","volume":"5","author":"A Fellgiebel","year":"2006","unstructured":"Fellgiebel A, M\u00fcller MJ, Ginsberg L (2006) CNS manifestations of Fabry\u2019s disease. Lancet Neurol 5:791\u2013795","journal-title":"Lancet Neurol"},{"key":"211_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncpneuro0407","volume":"3","author":"AT M\u00f8ller","year":"2007","unstructured":"M\u00f8ller AT, Jensen TS (2007) Neurological manifestations in Fabry\u2019s disease. Nat Clin Pract Neurol 3:95\u2013106","journal-title":"Nat Clin Pract Neurol"},{"key":"211_CR10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1742-1241.2009.02115.x","volume":"63","author":"O Lidove","year":"2009","unstructured":"Lidove O, Chauveheid MP, Caillaud C, Froissart R, Benoist L, Alamowitch S, Doan S, Szalat R, Baumann N, Alexandra JF, Lavall\u00e9e P, Klein I, Vuillemet F, Sedel F, Sacr\u00e9 K, Samson Y, Roullet E, Papo T (2009) Aseptic meningitis and ischemic stroke in Fabry disease. Int J Clin Pract 63:1663\u20131667","journal-title":"Int J Clin Pract"},{"key":"211_CR11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1352458508092355","volume":"14","author":"P Invernizzi","year":"2008","unstructured":"Invernizzi P, Bonometti MA, Turri E, Benedetti MD, Salviati A (2008) A case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble? Mult Scler 14:1003\u20131006","journal-title":"Mult Scler"},{"key":"211_CR12","unstructured":"Clavelou P, Besson G (2007) Neurological aspects of Fabry disease. Presse Med 36 Spec No 1:1S65\u2013S68"},{"key":"211_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65\u201377","journal-title":"Pharmacol Ther"},{"key":"211_CR14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1445-5994.2007.01366.x","volume":"37","author":"M Low","year":"2007","unstructured":"Low M, Nicholls K, Tubridy N, Hand P, Velakoulis D, Kiers L, Mitchell P, Becker G (2007) Neurology of Fabry disease. Intern Med J 37:436\u2013447","journal-title":"Intern Med J"},{"key":"211_CR15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","volume":"119","author":"SM Laaksonen","year":"2008","unstructured":"Laaksonen SM, R\u00f6ytt\u00e4 M, J\u00e4\u00e4skel\u00e4inen SK, Kantola I, Penttinen M, Falck B (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119:1365\u20131372","journal-title":"Clin Neurophysiol"},{"key":"211_CR16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.21606","volume":"41","author":"R Liguori","year":"2010","unstructured":"Liguori R, Di Stasi V, Bugiardini E, Mignani R, Burlina A, Borsini W, Baruzzi A, Montagna P, Donadio V (2010) Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve 41:409\u2013412","journal-title":"Muscle Nerve"},{"issue":"Suppl 443","key":"211_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1651-2227.2003.tb00219.x","volume":"92","author":"G Conti","year":"2003","unstructured":"Conti G, Sergi B (2003) Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous female. Acta Paediatr 92(Suppl 443):33\u201337","journal-title":"Acta Paediatr"},{"key":"211_CR18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1212\/01.wnl.0000173030.70057.eb","volume":"65","author":"A Fellgiebel","year":"2005","unstructured":"Fellgiebel A, M\u00fcller MJ, Mazanek M, Baron K, Beck M, Stoeter P (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65:600\u2013602","journal-title":"Neurology"},{"issue":"Suppl 451","key":"211_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08035320600618908","volume":"95","author":"L Ginsberg","year":"2006","unstructured":"Ginsberg L, Manara R, Valentine AR, Kendall B, Burlina AP (2006) Magnetic resonance imaging changes in Fabry disease. Acta Paediatr 95(Suppl 451):57\u201362","journal-title":"Acta Paediatr"},{"key":"211_CR20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","volume":"255","author":"AP Burlina","year":"2008","unstructured":"Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina A, Lidove O (2008) The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 255:738\u2013744","journal-title":"J Neurol"},{"key":"211_CR21","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","volume":"366","author":"A Rolfs","year":"2005","unstructured":"Rolfs A, B\u00f6ttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, L\u00f6hr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794\u20131796","journal-title":"Lancet"},{"key":"211_CR22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/01.wnl.0000338566.54190.8a","volume":"72","author":"A Fellgiebel","year":"2009","unstructured":"Fellgiebel A, Keller I, Marin D, M\u00fcller MJ, Schermuly I, Yakushev I, Bellh\u00e4user H, Kinateder M, Beck M, Stoeter P (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72:63\u201368","journal-title":"Neurology"},{"key":"211_CR23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","volume":"33","author":"DF Moore","year":"2002","unstructured":"Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, Schiffmann R (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525\u2013531","journal-title":"Stroke"},{"key":"211_CR24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","volume":"251","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251:564\u2013570","journal-title":"J Neurol"},{"key":"211_CR25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF03324669","volume":"18","author":"S Buechner","year":"2006","unstructured":"Buechner S, Luzzi C, Mannucci M, Massi D, Borsini W (2006) Diagnosis of Anderson-Fabry\u2019s disease in over seventy year-old women: description of two cases. Aging Clin Exp Res 18:340\u2013343","journal-title":"Aging Clin Exp Res"},{"key":"211_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"211_CR27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338\u2013346","journal-title":"Ann Intern Med"},{"key":"211_CR28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/003693305700200504","volume":"2","author":"J Rankin","year":"1957","unstructured":"Rankin J (1957) Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 2:200\u2013215","journal-title":"Scott Med J"},{"key":"211_CR29","doi-asserted-by":"crossref","unstructured":"The EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"211_CR30","first-page":"315","volume-title":"Fabry disease: perspectives from 5\u00a0years of FOS","author":"C Whybra","year":"2006","unstructured":"Whybra C, B\u00e4hner F, Baron K (2006) Measurement of disease severity and progression in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5\u00a0years of FOS. Oxford Pharmagenesis, Oxford, pp 315\u2013322"},{"key":"211_CR31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1742-1241.2006.01237.x","volume":"61","author":"O Lidove","year":"2007","unstructured":"Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T (2007) Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 61:293\u2013302","journal-title":"Int J Clin Pract"},{"key":"211_CR32","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","volume":"69","author":"RM Schaefer","year":"2009","unstructured":"Schaefer RM, Tylki-Szymanska A, Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69:2179\u20132205","journal-title":"Drugs"},{"key":"211_CR33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"211_CR34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","volume":"11","author":"JC Lubanda","year":"2009","unstructured":"Lubanda JC, Anijalg E, Bzd\u00fach V, Thurberg BL, B\u00e9nichou B, Tylki-Szymanska A (2009) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11:256\u2013264","journal-title":"Genet Med"},{"key":"211_CR35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"211_CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153\u2013158","journal-title":"Heart"},{"key":"211_CR37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1399-0004.2008.01012.x","volume":"74","author":"R Parini","year":"2008","unstructured":"Parini R, Rigoldi M, Santus F, Furlan F, De Lorenzo P, Valsecchi G, Concolino D, Strisciuglio P, Feriozzi S, Di Vito R, Ravaglia R, Ricci R, Morrone A (2008) Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson\u2013Fabry disease: testing the effects with the Mainz Severity Score Index. Clin Genet 74:260\u2013266","journal-title":"Clin Genet"},{"key":"211_CR38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","volume":"66","author":"L Spinelli","year":"2004","unstructured":"Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, Lo Surdo N, Federico S, Cianciaruso B (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry\u2019s disease. Clin Genet 66:158\u2013165","journal-title":"Clin Genet"},{"key":"211_CR39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2362.2006.01701.x","volume":"36","author":"D Hajioff","year":"2006","unstructured":"Hajioff D, Hegemann S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, Mehta A, Keilmann A (2006) Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36:663\u2013667","journal-title":"Eur J Clin Invest"},{"key":"211_CR40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Brys M, Marthol H, Stemper B, D\u00fctsch M (2004) Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62:1066\u20131072","journal-title":"Neurology"},{"key":"211_CR41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A, European Investigators FOS (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2013a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535\u2013542","journal-title":"Clin J Pain"},{"key":"211_CR42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"R Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703\u2013710","journal-title":"Muscle Nerve"},{"key":"211_CR43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","volume":"34","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, McArthur JC, Wagner K (2006) Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 34:53\u201356","journal-title":"Muscle Nerve"},{"key":"211_CR44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","volume":"17","author":"A Cousins","year":"2008","unstructured":"Cousins A, Lee P, Rorman D, Raas-Rothschild A, Banikazemi M, Waldek S, Thompson L (2008) Home-based infusion therapy for patients with Fabry disease. Br J Nurs 17:653\u2013657","journal-title":"Br J Nurs"},{"key":"211_CR45","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.12968\/bjon.2007.16.22.27768","volume":"16","author":"DA Hughes","year":"2007","unstructured":"Hughes DA, Mlilligan A, Mehta A (2007) Home therapy for lysosomal storage disorders. Br J Nurs 16:1384, 1386\u20131389","journal-title":"Br J Nurs"},{"key":"211_CR46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","volume":"21","author":"GE Linthorst","year":"2006","unstructured":"Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE (2006) Home treatment for Fabry disease: practice guidelines based on 3\u00a0years experience in The Netherlands. Nephrol Dial Transplant 21:355\u2013360","journal-title":"Nephrol Dial Transplant"},{"key":"211_CR47","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","volume":"39","author":"MR Filling-Katz","year":"1989","unstructured":"Filling-Katz MR, Merrick HF, Fink JK, Miles RB, Sokol J, Barton NW (1989) Carbamazepine in Fabry\u2019s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 39:598\u2013600","journal-title":"Neurology"},{"key":"211_CR48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025127723729","volume":"26","author":"M Ries","year":"2003","unstructured":"Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M (2003) Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 26:413\u2013414","journal-title":"J Inherit Metab Dis"},{"key":"211_CR49","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00415-007-0533-8","volume":"254","author":"W Schreiber","year":"2007","unstructured":"Schreiber W, Udvardi A, Kristoferitsch W (2007) Chronic meningitis and lacunar stroke in Fabry disease. J Neurol 254:1447\u20131449","journal-title":"J Neurol"},{"key":"211_CR50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(95)00156-5","volume":"65","author":"A Caraceni","year":"1996","unstructured":"Caraceni A, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de Conno F, Cleeland CS (1996) A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 65:87\u201392","journal-title":"Pain"},{"key":"211_CR51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","volume":"30","author":"R Melzack","year":"1987","unstructured":"Melzack R (1987) The short-form McGill Pain Questionnaire. Pain 30:191\u2013197","journal-title":"Pain"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10072-009-0211-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T01:53:51Z","timestamp":1711331631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-009-0211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,19]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1007\/s10072-009-0211-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,19]]}}}